Overview

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Status:
Recruiting

Trial end date:
2022-05-22

Target enrollment:

Participant gender:

Summary

This phase II trial studies the side effects of salsalate when added to venetoclax and decitabine or azacitidine in treating patients with acute myeloid leukemia or myelodysplasia/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Phase:

Phase 2

Details

Lead Sponsor:

Rutgers, The State University of New Jersey

Collaborator:

National Cancer Institute (NCI)

Treatments:

Azacitidine
Decitabine
Salicylsalicylic acid
Sodium Salicylate
Venetoclax